Charles River Laboratories International, Inc.CRLNYSE
Loading
EBITDA Over TimeExpanding
Percentile Rank86
3Y CAGR-2.6%
5Y CAGR+3.5%
Year-over-Year Change
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
-2.6%/yr
vs +18.1%/yr prior
5Y CAGR
+3.5%/yr
Recent deceleration
Acceleration
-20.7pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $911.15M | +56.8% |
| 2024 | $581.14M | -43.7% |
| 2023 | $1.03B | +4.7% |
| 2022 | $986.15M | +20.2% |
| 2021 | $820.16M | +6.7% |
| 2020 | $768.47M | +36.5% |
| 2019 | $563.06M | +11.0% |
| 2018 | $507.23M | +10.8% |
| 2017 | $457.89M | +21.4% |
| 2016 | $377.29M | - |